Kura Oncology (NASDAQ:KURA) Shares Gap Up - Here's What Happened

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) shares gapped up prior to trading on Monday . The stock had previously closed at $5.69, but opened at $5.95. Kura Oncology shares last traded at $5.81, with a volume of 285,233 shares traded.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Mizuho cut their target price on shares of Kura Oncology from $32.00 to $30.00 and set an "outperform" rating on the stock in a report on Monday, May 19th. Wedbush reiterated an "outperform" rating and issued a $36.00 target price on shares of Kura Oncology in a report on Tuesday, April 8th. Barclays cut their target price on shares of Kura Oncology from $32.00 to $11.00 and set an "overweight" rating on the stock in a report on Friday, May 2nd. JMP Securities reiterated a "market outperform" rating and issued a $28.00 target price on shares of Kura Oncology in a report on Wednesday. Finally, Wall Street Zen lowered shares of Kura Oncology from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $24.50.

Kura Oncology Trading Up 0.5%

The firm has a market capitalization of $558.41 million, a PE ratio of -2.73 and a beta of 0.50. The firm's fifty day moving average is $6.07 and its two-hundred day moving average is $7.82. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The business had revenue of $14.11 million for the quarter, compared to analyst estimates of $39.08 million. On average, equities analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Institutional Trading of Kura Oncology

Several hedge funds have recently added to or reduced their stakes in KURA. State of Wyoming bought a new stake in shares of Kura Oncology in the first quarter valued at approximately $48,000. Virtus ETF Advisers LLC grew its stake in Kura Oncology by 71.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock worth $64,000 after buying an additional 3,061 shares in the last quarter. Pallas Capital Advisors LLC purchased a new position in Kura Oncology in the 1st quarter worth approximately $66,000. Flower City Capital purchased a new position in Kura Oncology in the 1st quarter worth approximately $79,000. Finally, Magnetar Financial LLC purchased a new position in Kura Oncology in the 1st quarter worth approximately $79,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.